196 related articles for article (PubMed ID: 9667853)
1. Farnesyltransferase inhibitors versus Ras inhibitors.
Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
[TBL] [Abstract][Full Text] [Related]
2. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.
Omer CA; Kohl NE
Trends Pharmacol Sci; 1997 Nov; 18(11):437-44. PubMed ID: 9426472
[TBL] [Abstract][Full Text] [Related]
3. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Gibbs JB; Oliff A
Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
[TBL] [Abstract][Full Text] [Related]
4. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
5. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
8. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
Singh SB; Zink DL; Williams M; Polishook JD; Sanchez M; Silverman KC; Lingham RB
Bioorg Med Chem Lett; 1998 Aug; 8(16):2071-6. PubMed ID: 9873488
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
10. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors. Preclinical development.
Kohl NE
Ann N Y Acad Sci; 1999; 886():91-102. PubMed ID: 10667207
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
13. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
[TBL] [Abstract][Full Text] [Related]
14. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical development of farnesyltransferase inhibitors.
Lobell RB; Kohl NE
Cancer Metastasis Rev; 1998 Jun; 17(2):203-10. PubMed ID: 9770117
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
17. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Moasser MM; Rosen N
Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
[TBL] [Abstract][Full Text] [Related]
18. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
19. Alpha-cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation.
Poradosu E; Gazit A; Reuveni H; Levitzki A
Bioorg Med Chem; 1999 Aug; 7(8):1727-36. PubMed ID: 10482464
[TBL] [Abstract][Full Text] [Related]
20. RAS and leukemia: from basic mechanisms to gene-directed therapy.
Beaupre DM; Kurzrock R
J Clin Oncol; 1999 Mar; 17(3):1071-9. PubMed ID: 10071302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
